Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00533572 · ClinicalTrials.gov registry record
Recessive Dystrophic Epidermolysis Bullosa Screening for Possible Gene Transfer
A clinical trial, sponsored by Stanford University.
- Terminated
- Registry status
- 1
- Enrollment target
NCT00533572: Clinical Trial study, sponsored by Stanford University.
NCT00533572 is a clinical trial that was terminated before completion, run by Stanford University. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00533572 was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- 1 participants
- Enrollment target
Study Summary
Recessive Dystrophic Epidermolysis Bullosa (RDEB) is a severe inherited blistering skin disease caused by absence of type VII collagen. Patients with RDEB develop large, severly painful blisters and open wounds from minor trauma to their skin. In the future, we hope to start a gene transfer study on a specific group of RDEB subjects and we are screening subjects for that potential trial now.
Primary Outcome
Documentation of disease
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2007-08 |
| Est. Completion | 2008-08 |
Why NCT00533572 stopped before completion
NCT00533572 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 1 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00533572 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00533572 about?
NCT00533572 is a clinical study titled "Recessive Dystrophic Epidermolysis Bullosa Screening for Possible Gene Transfer". Recessive Dystrophic Epidermolysis Bullosa (RDEB) is a severe inherited blistering skin disease caused by absence of type VII collagen. Patients with RDEB develop large, severly painful blisters and open wounds from minor trauma to their skin. In the future, we hope to start a gene transfer study on...
What is the current status of trial NCT00533572?
This trial is currently terminated. The enrollment target is 1 participants. The study started on 2007-08. Estimated completion is 2008-08.
Who is sponsoring clinical trial NCT00533572?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia